Search Result

Results for "

PD-1 receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PD-1/PD-L1 (20) Adenosine Receptor (1) AMPK (1) Androgen Receptor (1) Apoptosis (1) Aryl Hydrocarbon Receptor (3) c-Kit (2) CMV (1) CTLA-4 (1) Discoidin Domain Receptor (2) Dopamine Receptor (3) Drug-Linker Conjugates for ADC (1) EGFR (1) Endogenous Metabolite (2) FLT3 (2) FXR (1) IFNAR (1) iGluR (3) Interleukin Related (5) LILRB (1) MAP4K (1) mGluR (2) Monoamine Oxidase (1) Phosphatase (1) Prostaglandin Receptor (3) Reactive Oxygen Species (ROS) (1) Reference Standards (1) SHP1 (1) TAM Receptor (3) TNF Receptor (2) Toll-like Receptor (TLR) (2) Trace Amine-associated Receptor (TAAR) (1) Trk Receptor (2) VEGFR (2)
By Research Areas:	Cancer (34) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (12) Neurological Disease (12)

By Targets:

PD-1/PD-L1 (20)

Adenosine Receptor (1)

AMPK (1)

Androgen Receptor (1)

Apoptosis (1)

Aryl Hydrocarbon Receptor (3)

c-Kit (2)

CMV (1)

CTLA-4 (1)

Discoidin Domain Receptor (2)

Dopamine Receptor (3)

Drug-Linker Conjugates for ADC (1)

EGFR (1)

Endogenous Metabolite (2)

FLT3 (2)

FXR (1)

IFNAR (1)

iGluR (3)

Interleukin Related (5)

LILRB (1)

MAP4K (1)

mGluR (2)

Monoamine Oxidase (1)

Phosphatase (1)

Prostaglandin Receptor (3)

Reactive Oxygen Species (ROS) (1)

Reference Standards (1)

SHP1 (1)

TAM Receptor (3)

TNF Receptor (2)

Toll-like Receptor (TLR) (2)

Trace Amine-associated Receptor (TAAR) (1)

Trk Receptor (2)

VEGFR (2)

By Research Areas:

Cancer (34)

Cardiovascular Disease (1)

Infection (3)

Inflammation/Immunology (12)

Neurological Disease (12)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: PD-1/PD-L1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9902

Pembrolizumab Maximum Cited Publications 30 Publications Verification MK-3475; Lambrolizumab	PD-1/PD-L1	Cancer
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

HY-P9903

Nivolumab 20+ Cited Publications BMS-936558; ONO-4538; MDX-1106	PD-1/PD-L1	Infection Cancer
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

HY-16961

Sitravatinib 5+ Cited Publications MGCD516; MG-516	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Inflammation/Immunology Cancer
Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .

HY-P99052

Tislelizumab 3 Publications Verification BGB-A317	PD-1/PD-L1	Inflammation/Immunology Cancer
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .

HY-P99166

Vudalimab XMAB-20717	PD-1/PD-L1 CTLA-4	Inflammation/Immunology Cancer
Vudalimab is a potent dual *PD-1* and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .

HY-P99489

Budigalimab ABBV 181; PR 1648817	PD-1/PD-L1	Inflammation/Immunology Cancer
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .

HY-P99618

Fidasimtamab IBI-315; BH2950	EGFR PD-1/PD-L1	Cancer
Fidasimtamab is a bispecific antibody targeting human epidermal growth factor receptor 2 (Her2) and programmed death protein 1 (PD-1), with a K_a of 3.55e-10 M for human Her2 and a K_a of 1.17e-9 M for human *PD-1. Fidasimtamab cross-links Her2-positive tumor cells with PD-1*-positive T cells to form immune synapses, blocks *PD-1*-ligand interactions, preserves antibody-dependent cellular cytotoxicity, induces gasdermin B (GSDMB)-mediated pyroptosis, and activates T cells. Fidasimtamab is applicable to relevant research on Her2-positive gastric cancer .

HY-13993

Ro 25-6981 5+ Cited Publications	iGluR	Neurological Disease
Ro 25-6981 is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 has the potential for the research of parkinson's disease (PD) .

HY-113366

Prostaglandin J2 PGJ2	Prostaglandin Receptor Endogenous Metabolite	Neurological Disease
Prostaglandin J2 (PGJ2), an endogenous metabolite of Prostaglandin D2 (PGD2; HY-101988), is a potent *PGD2 receptor* (DP) agonist with K_i*s of 0.9 nM and 6.6 nM for hDP and hCRTH2, respectively. Prostaglandin J2 stimulates intracellular cyclic AMP production with an EC₅₀ value of 1.2 nM. Prostaglandin J2 induces oxidative stress and neuronal apoptosis. Prostaglandin J2 induces the accumulation/aggregation of ubiquitinated (Ub) proteins. Prostaglandin J2 is highly neurotoxic and potentially contributes to many neurodegenerative conditions, including Alzheimer's (AD) and Parkinson's diseases (PD)* .

HY-P99203

Cemiplimab REGN-2810; SAR-439684	PD-1/PD-L1	Cancer
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .

HY-P5005

VIPhyb	CMV PD-1/PD-L1	Infection Inflammation/Immunology Cancer
VIPhyb is a vasoactive intestinal polypeptide (VIP) receptor antagonist. VIPhyb can inhibit VIP signaling, increase T-cell immunity and downregulate *PD1*. VIPhyb can inhibit cancer cell proliferation. VIPhyb can reduce inflammatory cytokine expression. VIPhyb can enhance viral clearance. VIPhyb can be used for the researches of cancer, infection and inflammation and immunology, such as non-small cell lung cancer (NSCLC), cytomegalovirus infection and colitis .

HY-13993A

Ro 25-6981 Maleate 5+ Cited Publications	iGluR	Neurological Disease
Ro 25-6981 Maleate is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 Maleat shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 Maleate has the potential for the research of parkinson's disease (PD) .

HY-N3431

Kaempferol-7-O-rhamnoside	AMPK PD-1/PD-L1 FXR Reactive Oxygen Species (ROS)	Cardiovascular Disease
Kaempferol-7-O-rhamnoside is a *PD-1/PD-L1* inhibitor and farnesoid X receptor (FXR) agonist. Kaempferol-7-O-rhamnoside demonstrates cardioprotective potential targeting the AMPKα1 signaling pathway. Kaempferol-7-O-rhamnoside significantly upregulates the mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Kaempferol-7-O-rhamnoside reverses APAP-induced reduction of glutathione (GSH) content and increase of ROS production in L02 cells. Kaempferol-7-O-rhamnoside has the potential for heart failure .

HY-12964

SGI-7079 3 Publications Verification	TAM Receptor	Cancer
SGI-7079 is a selective, ATP-competitive, orally active inhibitor of the receptor tyrosine kinase Axl. SGI-7079 blocks Axl-mediated signaling pathways such as NF-κB activation and MMP-9 expression, thereby inhibiting tumor cell proliferation, migration and invasion. SGI-7079 is mainly used in the research of malignant tumors such as inflammatory breast cancer and bladder cancer, as well as in combination with immunization (used in combination with PD-1 therapy)[1][2][3].

HY-P991740

IBI-363	PD-1/PD-L1 Interleukin Related	Cancer
IBI-363 is a PD-1/IL-2 bispecific antibody with functions of blocking the PD-1/PD-L1 pathway and activating the IL-2 pathway. The IL-2 arm of IBI-363 retains affinity for IL-2Rα but attenuates binding ability to IL-2Rβ and IL-2Rγ to reduce toxicity. The PD-1 binding arm of IBI-363 enables PD-1 blockade and selective delivery of IL-2. IBI-363 can be used in cancer research, such as non-small cell lung cancer .

HY-147218

PF-07265807 ARRY-067	TAM Receptor	Cancer
PF-07265807 (ARRY-067) is a kinase inhibitor with primary targets AXL, MERTK, and TYRO3. PF-07265807 acts as an immunomodulator that cross-activates CD8 ⁺ T cells by enhancing dendritic cell function. PF-07265807 blocks downstream signal transduction of AXL and MERTK, and inhibits the proliferation and migration of tumor cells with high expression of these two kinases. PF-07265807 is applicable to research related to advanced or metastatic solid tumors, such as colorectal cancer .

HY-P990172

Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2)	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG1. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) can be used for the research of cancer.

HY-P990171

Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2)	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG2a. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) can be used for the research of cancer.

HY-108237

Naxagolide (+)-PHNO; Dopazinol	Dopamine Receptor	Neurological Disease
Naxagolide ((+)-PHNO; Dopazinol) is a potent dopamine D2 (Dopamine Receptor) agonist. Naxagolide has the potential for the research of parkinson's disease (PD) .

HY-148867

UCM-1306	Dopamine Receptor	Neurological Disease
UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM). UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD) .

HY-120553

B-355252 1 Publications Verification	Apoptosis	Neurological Disease
B355252, a phenoxy thiophene sulfonamide small molecule, is a potent NGF receptor agonist. B355252 potentiates NGF-induced neurite outgrowth. B355252 protects ischemic neurons from neuronal loss by attenuating DNA damage, reducing ROS production and the LDH level, and preventing neuronal apoptosis. B355252 has anti-apoptotic effects in glutamate-induced excitotoxicity, as well as in a murine hippocampal cell line (HT22) model of Parkinson disease (PD) .

HY-147319

RTI-7470-44	Trace Amine-associated Receptor (TAAR)	Neurological Disease
RTI-7470-44 is a potent, selective and blood-brain barrier (BBB) penetrant *human trace amine-associated receptor* subtype 1 (hTAAR1) antagonist with an IC₅₀ value of 8.4 nM and a K_i** value of 0.3 nM. RTI-7470-44 has moderate metabolic stability, and a favorable preliminary off-target profile. RTI-7470-44 can increase the spontaneous firing rate of mouse ventral tegmental area (VTA) dopaminergic neurons. RTI-7470-44 can be used for researching schizophrenia, agent addiction, and Parkinson’s disease (PD) .

HY-P990067

Evunzekibart ATOR-1017	TNF Receptor	Cancer
Evunzekibart (ATOR-1017) is an Fc-γ receptor conditional 4-1BB agonist and IgG4-type antibody. Evunzekibart can be used as monotherapy or in combination with anti-PD1 to exert anticancer activity.

HY-159643

NDI-101150	MAP4K IFNAR Interleukin Related	Inflammation/Immunology Cancer
NDI-101150 is an orally active, potent and selective hematopoietic progenitor cell kinase 1 (HPK1) inhibitor with an IC₅₀ of 0.7 nM. NDI-101150 blocks HPK1-mediated negative regulation of immune receptor signaling, inhibits immunosuppression of T cell activation, enhances antigen-specific antibody production and augments B-cell activation. NDI-101150 inhibits tumor growth in syngeneic tumor models, establishes durable antitumor immune memory, and synergizes with anti-PD1 to enhance exhausted T cell activity and drive tumor regressions. NDI-101150 can be used for the research of cancer, such as breast cancer and colon cancer .

HY-155847

LYP-IN-3	Phosphatase PD-1/PD-L1	Inflammation/Immunology Cancer
LYP-IN-3 is a selective, orally active and reversible lymphoid-tyrosine phosphatase (LYP) inhibitor (IC₅₀ = 2.55 μM, Ki = 0.93 μM). D34 exhibits high selectivity of PTP1B, PTPN12, PTPN5 and SSH2. LYP-IN-3 regulates the T-cell receptor (TCR) signaling by specifically inhibiting LYP. LYP-IN-3 does not significantly inhibit MC38 cell viability; its anti-tumor effect stems from immune regulation. LYP-IN-3 can significantly upregulate PD-L1 or *PD-1* expression in different immune cells. LYP-IN-3 facilitates T-cell infiltration and enhances T-cell functions. LYP-IN-3 synergizes with PD-L1 blockade can significantly improve colorectal tumor regression. LYP-IN-3 can be used for the study of colorectal cancer .

HY-136220

AHR antagonist 5	Aryl Hydrocarbon Receptor	Cancer
AHR antagonist 5, a potent and orally active aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018195397, example 39, has an IC₅₀ of < 0.5 μΜ. AHR antagonist 5 significantly inhibits tumor growth combined with checkpoint inhibitor anti-PD-1 .

HY-P99957

Zeluvalimab AMG-404	PD-1/PD-L1	Cancer
Zeluvalimab (AMG-404) is a monoclonal antibody targeting the **PD-1 receptor** that can be used for the research of cancer .

HY-16961A

Sitravatinib malate MGCD516 malate; MG-516 malate	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Inflammation/Immunology Cancer
Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .

HY-144497

HE-S2	PD-1/PD-L1 Toll-like Receptor (TLR) Drug-Linker Conjugates for ADC	Infection Cancer
HE-S2 is an antibody-drug conjugate triggering a potent antitumor immune response. HE-S2 acts by blocking the *PD-1/PD-L1* interaction and activating the Toll-like receptor 7/8 (TLR7/8) signaling pathway. HE-S2 has remarkable antitumor activity .

HY-169859

EP4 receptor antagonist 7	Prostaglandin Receptor Interleukin Related	Inflammation/Immunology Cancer
EP4 receptor antagonist 7 (Compound 14) is an antagonist of the prostaglandin E2 (PGE2) receptor subtype EP4 with an IC₅₀ value of 1.1 nM. EP4 receptor antagonist 7 inhibits PGE2-induced β-arrestin recruitment in HEK293 cells with an IC₅₀ value of 0.9 nM. EP4 receptor antagonist 7 decreases PGE2-induced expression of mRNA encoding IL-4, macrophage mannose receptor 1 (Mrc1), chitinase-like protein 3 (Chil3), chemokine (C-X-C) motif ligand 1 (Cxcl1), triggering receptor expressed on myeloid cells 2 (Trem2), and arginase-1 (Arg1), in RAW 264.7 macrophages. EP4 receptor antagonist 7 combined with an anti-PD-1 antibody inhibits tumor growth and increases infiltration of CD ⁸⁺ T cells into tumors in a CT26 murine colon cancer model .

HY-120826

A2AAR/hMAO-B-IN-1	Monoamine Oxidase Adenosine Receptor	Neurological Disease
A2AAR/hMAO-B-IN-1 (compoudn 17) is a non-xanthine dual-target inhibitor targeting the A2A adenosine receptor (A2AAR) (IC₅₀: 34.9 nM) andMAO-B (Ki: 39.5 nM, human). A2AAR/hMAO-B-IN-1 inhibits A2AAR-induced cAMP accumulation and exhibits competitive, reversible inhibition of MAO-B. A2AAR/hMAO-B-IN-1 can be used in the study of neurodegenerative diseases such as Parkinson's disease (PD) .

HY-153543

TLR7/8 agonist 8	Toll-like Receptor (TLR)	Cancer
TLR7/8 agonist 8 (compound 24m) is a potent *toll-like receptor* 7/8 (TLR7/8) dual agonist, with EC₅₀s of 27 and 12 nM for hTLR7 and hTLR8*, respectively. TLR7/8 agonist 8 can improve the antitumor activity of PD-1/PD-L1* blockade .

HY-P99963

Sudubrilimab HS636	PD-1/PD-L1	Cancer
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .

HY-118238

Remeglurant MRZ-8456	mGluR	Neurological Disease
Remeglurant (MRZ-8456) acts as a selective, orally active and allosteric antagonist of the mGlu5 receptor, with an IC₅₀ of 13 nM. Remeglurant (MRZ-8456) can be used in the research for dyskinesia in Parkinson’s disease (PD) .

HY-107505

CBiPES hydrochloride	mGluR	Neurological Disease
CBiPES hydrochloride is a mGlu2 receptor positive allosteric modulator (EC₅₀: 92.8 nM). CBiPES hydrochloride attenuates stress-induced hyperthermia and PCP-induced hyperlocomotor activity. CBiPES hydrochloride can be used for research of neurological disease, such as Parkinson's disease (PD) .

HY-W400801

Denfivontinib hydrochloride G-749 hydrochloride	TAM Receptor	Cancer
Denfivontinib (G-749) hydrochloride is an AXL inhibitor that has synergistic antitumor effects with the PD-1 inhibitor Pembrolizumab (HY-P9902). Denfivontinib can enhance the NOD-like receptor pathway, thereby promoting the formation of the NLRP3 inflammasome .

HY-P991529

AGEN-2373	TNF Receptor	Inflammation/Immunology Cancer
AGEN-2373 is a conditionally active agonist antibody targeting the co-stimulatory receptor CD137. GEN-2373 binds to CD137 without disruption of ligand binding. AGEN-2373 stimulates CD137 under receptor clustering conditions. AGEN-2373 can enhance T cell activity when combined with other checkpoint modulators (e.g. PD-1 antagonist and OX40 agonist). AGEN-2373 can be studied in research for human malignancies .

HY-N12537A

(2R,3S)-PD-1/PD-L1-IN-38	Aryl Hydrocarbon Receptor PD-1/PD-L1	Cancer
(2R,3S)-PD-1/PD-L1-IN-38 (Compound (±)-13e) is an orally active Ah receptor (AhR) antagonist with in vivo and in vitro anticancer activity. (2R,3S)-PD-1/PD-L1-IN-38 promotes the secretion of INF-γ by CD8 ⁺T cells and inhibits the signal transduction of PD-1/PD-L1 .

HY-108237R

Naxagolide (Standard) (+)-PHNO (Standard); Dopazinol (Standard)	Dopamine Receptor Reference Standards	Neurological Disease
Naxagolide (Standard) is the analytical standard of Naxagolide. This product is intended for research and analytical applications. Naxagolide ((+)-PHNO; Dopazinol) is a potent dopamine D2 (Dopamine Receptor) agonist. Naxagolide has the potential for the research of parkinson's disease (PD) .

HY-13993B

Ro 25-6981 hydrochloride	iGluR	Neurological Disease
Ro 25-6981 hydrochloride is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 hydrochloride shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 hydrochloride has the potential for the research of parkinson's disease (PD) .

HY-136220A

AHR antagonist 5 hemimaleate	Aryl Hydrocarbon Receptor	Cancer
AHR antagonist 5 hemimaleate, a potent and orally active aryl hydrocarbon receptor (AHR) antagonist, has an IC₅₀ of < 0.5 µΜ. AHR antagonist 5 hemimaleate significantly inhibits tumor growth combined with checkpoint inhibitor anti-PD-1 (WO2018195397, example 39) .

HY-P992434

OSE-279	PD-1/PD-L1 SHP1 Interleukin Related	Cancer
OSE-279 is a high-affinity humanized monoclonal bivalent antibody targeting *PD-1, the recommended isotype control is HY-P99003. OSE-279 blocks PD-1* ligand binding, inhibits PDL1-induced SHP1 phosphorylation, restores T cell activation, and promotes reactivation of primary T cell effector functions. OSE-279 binds hFcRn receptor, predicts long half-life, induces CD4 and CD8 T cell proliferation, and promotes interleukin 2 and interferon gamma secretion. OSE-279 can be used for the research of advanced malignancies, colon cancer, hepatocarcinoma, mesothelioma .

HY-P992161

REGN-10597	Interleukin Related PD-1/PD-L1	Inflammation/Immunology Cancer
REGN-10597, composed of an anti-huPD-1-targeting antibody and IL2Ra-IL2 moiety, is a *PD-1*-dependent IL-2 agonist. REGN-10597 binds PD-1 to deliver masked native IL-2 to PD-1⁺ T cells, engaging trimeric IL-2 receptors to activate downstream signaling. REGN-10597 can be used for the research on melanoma, prostate cancer, colorectal cancer, and ovarian cancer .

HY-P992448

RC98	PD-1/PD-L1	Cancer
RC98 is a monoclonal antibody targeting programmed cell death ligand 1 (PD-L1) and acts as a selective PD-L1 inhibitor. RC98 binds specifically to human and cynomolgus monkey PD-L1. RC98 blocks the interaction between PD-L1 and its receptor PD-1 to reverse T-cell inactivation mediated by PD-1/PD-L1 signaling. RC98 enhances the cytotoxic T-lymphocyte-mediated anti-tumor immune response against PD-L1-expressing tumor cells. RC98 can be used for the research of tumor immunity and solid tumors .

HY-183845

HTL0039732	Prostaglandin Receptor	Cancer
HTL0039732 is an orally active antagonist of the prostaglandin EP4 receptor *(Prostaglandin E2 Receptor* EP4)*. HTL0039732 reverses PGE₂-induced differentiation toward M2-like macrophages. HTL0039732 exhibits efficacy in syngeneic tumor models and acts synergistically with PD-1/PD-L1* pathway blockers. HTL0039732 can be used for the research of advanced solid tumors .

HY-179476

3-Oxochol-5-en-24-oic acid	Androgen Receptor Endogenous Metabolite	Inflammation/Immunology Cancer
3-Oxochol-5-en-24-oic acid is a rare bile acid produced by the intestinal microbiota. 3-Oxochol-5-en-24-oic acid is a potent antagonist of the human androgen receptor (hAR), with an IC₅₀ of 119.4 nM. 3-Oxochol-5-en-24-oic acid has no significant agonistic or antagonistic effects on estrogen receptors (ER) or glucocorticoid receptors (GR). 3-Oxochol-5-en-24-oic acid effectively inhibits the growth of prostate cancer cells. In animal models, it enhances the efficacy of anti-PD-1 therapy by regulating the differentiation of CD8 ⁺ T cells. 3-Oxochol-5-en-24-oic acid can be used for research on regulating host immunity and anti-tumor studies .

HY-P992353

ES009	LILRB	Cancer
ES009 is a high-affinity LILRB2 antagonist, with IC₅₀ values of 14.07 nM and 18.61 nM for inhibiting hLILRB2-huANGPTL3 and hLILRB2-huANGPTL4, respectively. ES009 specifically blocks the interactions between LILRB2 and MHC class I as well as non-MHC ligands, thereby effectively inhibiting receptor activation. ES009 can reprogram anti-inflammatory myeloid cells and induce their conversion to a pro-inflammatory phenotype, and also reverse the T cell suppression mediated by macrophages. When combined with anti-PD-1 blockade therapy, ES009 synergistically enhances T cell activation. ES009 can be used in research related to advanced solid tumors and ovarian cancer .

Cat. No.	Product Name

HY-L109

Protein-protein Interaction Inhibitor Library

782 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.

However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 782 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Cat. No.	Product Name	Target	Research Area